These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 7627720)

  • 21. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors.
    Hasegawa S; Horibe K; Kawabe T; Kato K; Kojima S; Matsuyama T; Hirabayashi N
    Bone Marrow Transplant; 1998 Dec; 22(12):1191-7. PubMed ID: 9894723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I study of escalating doses of low-dose-rate, locoregional irradiation preceding Cytoxan-TBI for patients with chemotherapy-resistant non-Hodgkin's or Hodgkin's lymphoma.
    Song DY; Jones RJ; Welsh JS; Haulk TL; Korman LT; Noga S; Goodman S; Herman M; Mann R; Marcellus D; Vogelsang G; Ambinder RF; Abrams RA
    Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):166-71. PubMed ID: 12909229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic veno-occlusive disease post-bone marrow transplantation in children conditioned with busulfan and cyclophosphamide: incidence, risk factors, and clinical outcome.
    Ozkaynak MF; Weinberg K; Kohn D; Sender L; Parkman R; Lenarsky C
    Bone Marrow Transplant; 1991 Jun; 7(6):467-74. PubMed ID: 1908340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [High-dosage chemo-radiotherapy with autologous bone marrow transfusion in malignant lymphoma: indications and personal experience].
    Stahel RA; Jost LM; Burger J; Honegger HP; Brun del Re GP; Gmür J
    Schweiz Med Wochenschr; 1989 Jun; 119(25):911-7. PubMed ID: 2667131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C; Antin JH; Churchill WH; Come SE; Smith BR; Bubley GJ; Rosenthal DS; Rappaport JM; Ault KA; Schnipper LE
    J Clin Oncol; 1990 Apr; 8(4):648-56. PubMed ID: 2313334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
    Shim BY; Lee MA; Byun JH; Roh SY; Song CW; Park JN; Lee JW; Min WS; Hong YS; Kim CC
    Korean J Intern Med; 2004 Jun; 19(2):114-20. PubMed ID: 15366643
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Veno-occlusive disease of the liver following high-dose chemotherapy and autologous bone marrow transplantation in children with solid tumors: incidence, clinical course and outcome.
    Brugieres L; Hartmann O; Benhamou E; Zafrani ES; Caillaud JM; Patte C; Kalifa C; Flamant F; Lemerle J
    Bone Marrow Transplant; 1988 Jan; 3(1):53-8. PubMed ID: 3048471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical course and outcome of patients with Hodgkin's disease who progress after autologous transplantation.
    Varterasian M; Ratanatharathorn V; Uberti JP; Karanes C; Abella E; Momin F; Kasten-Sportes C; Al-Katib A; Lum L; Heilbrun LK
    Leuk Lymphoma; 1995 Dec; 20(1-2):59-65. PubMed ID: 8750624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regimen-related acute toxicities: pathophysiology, risk factors, clinical evaluation and preventive strategies.
    Klingemann HG; Shepherd JD; Reece DE; Barnett MJ; Nantel SH; Sutherland HJ; Spinelli JJ; Phillips GL
    Bone Marrow Transplant; 1994; 14 Suppl 4():S14-8. PubMed ID: 7728119
    [No Abstract]   [Full Text] [Related]  

  • 31. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.
    Garfin PM; Link MP; Donaldson SS; Advani RH; Luna-Fineman S; Kharbanda S; Porteus M; Weinberg KI; Agarwal-Hashmi R
    Biol Blood Marrow Transplant; 2015 Feb; 21(2):326-34. PubMed ID: 25445024
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
    Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
    J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation.
    Rosenthal J; Sender L; Secola R; Killen R; Millerick M; Murphy L; Cairo MS
    Bone Marrow Transplant; 1996 Jul; 18(1):185-91. PubMed ID: 8832013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
    N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation.
    El-Sayed MH; El-Haddad A; Fahmy OA; Salama II; Mahmoud HK
    Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1347-54. PubMed ID: 15618844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease.
    Yahalom J; Gulati S; Shank B; Clarkson B; Fuks Z
    Int J Radiat Oncol Biol Phys; 1989 Nov; 17(5):915-22. PubMed ID: 2478511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of relapsed and refractory Hodgkin's disease with high dose chemotherapy and autologous bone marrow transplantation.
    Brice P; Gisselbrecht C; Ferme C; Lepage E; Baruchel A; Marolleau JP; Gerota O; Boiron M
    Nouv Rev Fr Hematol (1978); 1991; 33(3):267-72. PubMed ID: 1956765
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preparation for marrow transplantation in Hodgkin's and non-Hodgkin's lymphoma using Bu/CY.
    Avalos BR; Klein JL; Kapoor N; Tutschka PJ; Klein JP; Copelan EA
    Bone Marrow Transplant; 1993 Aug; 12(2):133-8. PubMed ID: 8401359
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
    Brice P; Marolleau JP; Dombret H; Lepage E; Baruchel A; Adam M; Miclea JM; Sitthy X; Gisselbrecht C
    Bone Marrow Transplant; 1992 May; 9(5):337-42. PubMed ID: 1352162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.